NEW YORK (GenomeWeb News) – The Burzynski Research Institute has struck a research agreement with the University of Alabama at Birmingham, under which the school will provide bioinformatics and data management support for the company's glioma treatment studies.

BRI, a Houston-based company focused on using genomics and epigenomics for cancer studies, said that UAB's Biostatistics and Bioinformatics Shared Facility (BBSF) will support its Phase I and Phase II protocol studies of Antineoplaston therapy, a treatment for gliomas.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.